Facebook
Twitter
LinkedIn

Media Center

FAST/Fellows/CARB-X Round-Up June 2018
Facebook
Twitter
LinkedIn

FAST & Fellows Round-Up

  • Sandstone Diagnostics (FAST Fall 2013) presented results of digital male fertility risk assessment algorithm with men trying to conceive Read More
  • Ligandal (FAST Spring 2016) successfully used a ligand-targeted nanoparticle to deliver CRISPR into the nucleus of a T-cell Read More
  • Eidos Therapeutics (FAST Spring 2016) announced closing of approximately $122.2 million IPO Read More

CARB-X Updates

  • Powered by CARB-X company Melinta Therapeutics launched a new antibiotic stewardship program to fight against the global health threat of antimicrobial resistance Read More
  • CARB-X awards up to $8.6 million to California-based company Talis Biomedical to support the development of its molecular diagnostic system to speed diagnosis and appropriate treatment of chlamydia and gonorrhea, including drug-resistant infections Read More
  • CARB-X awards up to $3.5 million to California-based company MicrobeDx to support the development of its rapid diagnostic system for potentially life-threatening infections in the urinary tract Read More
  • Powered by CARB-X company Entasis Therapeutics announced initiation of clinical studies of novel oral beta-lactamase inhibitor ETX0282 Read More
  • Powered by CARB-X company Spero Therapeutics announced positive top-line data for two product candidates from its potentiator platform Read More. Spero also awarded a £250K grant to the University of Liverpool to help develop new antibiotic SPR206 Read More
  • Powered by CARB-X company T2 Biosystems received FDA clearance to market T2Bacteria Panel for detection of sepsis-causing pathogens Read More. T2 Biosystems also announced closing of a $52.6M public offering Read More
  • Powered by CARB-X company Tetraphase Pharmaceuticals announced that Everest Medicines, a biopharmaceutical company in China – which has the exclusive license to develop and commercialize eravacycline in China, Taiwan, Hong Kong, Macau, South Korea, and Singapore – submitted an IND to China’s Food and Drug Administration (CFDA) for a phase 3 clinical trial of eravacycline in complicated intra-abdominal infections. Tetraphase’s eravacycline NDA is under review in the U.S. Read More